{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    4,
    6,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_9",
        "affectedSection": "Synopsis; 3.1 Overview of Study Design; 10.1 Completion; 11.2 Sample Size Determination; 11.3 Efficacy Analysis; 17.9.1 Final OS Analysis/End of study",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Defined clinical cut-off for final CSR analysis, transition to long-term survival follow-up, and final OS analysis timing."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_9",
        "affectedSection": "8.2 Permitted Therapies; 8.3 Prohibited Therapies",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Clarified permitted and prohibited vaccinations, specifically restricting live-attenuated vaccines."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_8",
        "affectedSection": "Synopsis; 3.1 Overview of Study Design; 6 Dosage and Administration",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Introduced the option for subjects to switch from daratumumab IV to daratumumab subcutaneous (SC) administration."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_6",
        "affectedSection": "8.1.7 Management of Hepatitis B Virus Reactivation; 9.8 Safety Evaluations",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added monitoring and management protocols for Hepatitis B Virus (HBV) reactivation risk."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_9",
        "reasonText": "To define the clinical cut-off for the final CSR analysis and revise the end of study definition.",
        "category": "Administrative",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_8",
        "reasonText": "To provide flexibility for study investigators to prioritize patient safety during the global COVID-19 pandemic.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_6",
        "reasonText": "In response to identification of a new important risk (hepatitis B virus [HBV] reactivation).",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_5",
        "reasonText": "Following IDMC review, allow Arm A subjects access to daratumumab after confirmed disease progression.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_9",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "17.9.1",
        "afterText": "End of study defined as when all subjects still receiving daratumumab have access through another source, or all discontinued, or by 31 January 2026.",
        "summary": "Defined the specific end of study date and conditions."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_9",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "8.3",
        "afterText": "Restriction of live-attenuated and replication-competent viral vector vaccines.",
        "summary": "Added specific prohibitions for certain vaccine types."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_8",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1.3",
        "afterText": "Daratumumab SC 1800 mg administration via subcutaneous injection.",
        "summary": "Added subcutaneous route of administration for daratumumab."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.4.1.2",
        "beforeText": "Doses delayed for more than 4 weeks (Cycle 1 to 6) or 6 weeks (Cycle 7+) should be discontinued.",
        "afterText": "Doses delayed for more than 4 weeks (Cycle 1 to 6) or 6 weeks (Cycle 7+) should be discontinued, unless agreed upon with sponsor.",
        "summary": "Added flexibility for treatment continuation after prolonged delay upon sponsor consultation."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_5",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Time and Events Schedule",
        "beforeText": "Samples are requested at time of suspected CR/sCR and at 12, 18, 24, and 30 months.",
        "afterText": "Samples are requested at time of suspected CR/sCR and at 12, 18, 24, 30, 36, 48, and 60 months.",
        "summary": "Extended the duration of MRD monitoring timepoints."
      }
    ],
    "summary": {
      "impactCount": 4,
      "reasonCount": 4,
      "changeCount": 5
    }
  }
}